EL7.AI
StocksMedium•27 October 2026•
3 min read

Exosens raises 2026 revenue forecast to €558–570 million

Key Facts

1Exosens raised its 2026 revenue forecast to €558–570 million, from €520–540 million.
2The company raised its 2026 adjusted EBITDA forecast to €186–192 million, from €168–178 million.
3The company reported first-half 2026 revenue of €253.1 million, up 15.3% year on year.
4Revenue in the detection and imaging segment rose 24.3% to €77.4 million in the first half of 2026.
5The company set February 22, 2027, as the date for publishing its 2026 full-year results and 2027 guidance.

Exosens raised its 2026 revenue forecast to €558–570 million, from a previous range of €520–540 million, according to a company statement issued on September 17. The revision also covered adjusted EBITDA, which is now forecast at €186–192 million, compared with €168–178 million. The higher ranges reflect an improved outlook for annual performance as demand grows for the imaging and amplification technologies the company provides. The company had announced that its scheduled October 27 release would cover nine-month revenue and adjusted gross margin, before the market opened. Available information does not include the outcome of that release or a documented figure for third-quarter revenue growth.

Exosens said it revised its forecast amid “faster adoption of mission-critical imaging technologies” in drone, counter-drone and long-range surveillance applications. It also cited momentum in nuclear instrumentation linked to SMR technologies. These areas show the breadth of demand the company says it is seeing across defense, surveillance and nuclear applications. In its first-half 2026 results, the company said revenue in its detection and imaging segment rose 24.3% to €77.4 million, while revenue in its amplification segment increased 11.6% to €176.3 million. Total first-half revenue was €253.1 million, up 15.3% year on year and 11.4% on a like-for-like basis.

The company attributed first-half growth in its detection and imaging segment to contributions from acquisitions and like-for-like growth of 14.6%. It said demand in defense and surveillance markets remained supportive, particularly in drone and counter-drone applications, alongside continued strength in nuclear instrumentation. Over the same period, adjusted gross profit rose 16.5% to €129.9 million. Adjusted gross margin improved to 51.3% from 50.8% in the first half of 2025. These results provide context for the higher annual targets, but do not replace the nine-month figures the company scheduled for release in October.

In its first-quarter results announcement, the company had maintained a revenue forecast of €520–540 million and adjusted EBITDA of €168–178 million. In September, it raised the ranges to €558–570 million and €186–192 million, respectively. It also announced plans to double production capacity for cooled infrared cameras and triple thermal-camera production capacity during 2026. It kept expected capital expenditure at around 9% of revenue, excluding capitalized research and development expenses. Exosens describes itself as a technology company specializing in mission-critical, high-performance amplification, detection and imaging technologies.

Exosens set February 22, 2027, as the date for publishing its 2026 full-year results and said it would announce 2027 guidance then. This follows the October 27, 2026, release date for nine-month revenue and adjusted gross margin. The higher annual forecast includes a revenue range above the previous one, alongside a corresponding increase in the adjusted EBITDA range. The company also linked the revision to developments in demand for defense imaging and nuclear instrumentation. Full-year results and 2027 guidance are the next updates the company has scheduled on its performance.